» Articles » PMID: 38299275

Emerging Phytochemical Formulations for Management of Rheumatoid Arthritis: A Review

Overview
Journal Curr Drug Deliv
Specialty Pharmacology
Date 2024 Feb 1
PMID 38299275
Authors
Affiliations
Soon will be listed here.
Abstract

Rheumatoid arthritis (RA) is a T-cell-mediated chronic inflammatory disorder affecting 0.5-1% of the global population. The disease with unknown etiology causes slow destruction of joints, advancing to significant deterioration of an individual's quality of life. The present treatment strategy comprises the use of disease-modifying anti-rheumatic drugs (DMARDs) coupled with or without nonsteroidal anti-inflammatory drugs or glucocorticoids. Additionally, involves co-therapy of injectable biological DMARDs in case of persistent or recurrent arthritis. The availability of biological DMARDs and the implementation of the treat-to-target approach have significantly improved the outcomes for patients suffering from RA. Nevertheless, RA requires continuous attention due to inadequate response of patients, development of tolerance and severe side effects associated with long-term use of available treatment regimens. An estimated 60-90% of patients use alternative methods of treatment, such as herbal therapies, for the management of RA symptoms. Over the past few decades, researchers have exploring natural phytochemicals to alleviate RA and associated symptoms. Enormous plant-origin phytochemicals such as alkaloids, flavonoids, steroids, terpenoids and polyphenols have shown anti-inflammatory and immunomodulatory activity against RA. However, phytochemicals have certain limitations, such as high molecular weight, poor water solubility, poor permeability, poor stability and extensive first-pass metabolism, limiting absorption and bioavailability. The use of nanotechnology has aided to extensively improve the pharmacokinetic profile and stability of encapsulated drugs. The current review provides detailed information on the therapeutic potential of phytochemicals. Furthermore, the review focuses on developed phytochemical formulations for RA, with emphasis on clinical trials, regulatory aspects, present challenges, and future prospects.

References
1.
Rani R, Raina N, Sharma A, Kumar P, Tulli H, Gupta M . Advancement in nanotechnology for treatment of rheumatoid arthritis: scope and potential applications. Naunyn Schmiedebergs Arch Pharmacol. 2023; 396(10):2287-2310. DOI: 10.1007/s00210-023-02514-5. View

2.
Kesharwani D, Paliwal R, Satapathy T, Paul S . Rheumatiod Arthritis: An Updated Overview of Latest Therapy and Drug Delivery. J Pharmacopuncture. 2020; 22(4):210-224. PMC: 6970574. DOI: 10.3831/KPI.2019.22.029. View

3.
Madav Y, Barve K, Prabhakar B . Current trends in theranostics for rheumatoid arthritis. Eur J Pharm Sci. 2020; 145:105240. DOI: 10.1016/j.ejps.2020.105240. View

4.
Thakur S, Riyaz B, Patil A, Kaur A, Kapoor B, Mishra V . Novel drug delivery systems for NSAIDs in management of rheumatoid arthritis: An overview. Biomed Pharmacother. 2018; 106:1011-1023. DOI: 10.1016/j.biopha.2018.07.027. View

5.
Zheng M, Jia H, Wang H, Liu L, He Z, Zhang Z . Application of nanomaterials in the treatment of rheumatoid arthritis. RSC Adv. 2022; 11(13):7129-7137. PMC: 8695100. DOI: 10.1039/d1ra00328c. View